The apolipoprotein C3 test kit (immune turbidimetry/ELISA method) is used to quantitatively measure the ApoC3 content in serum or plasma in vitro. Its applicable population can be divided into the following categories according to clinical needs:
<1. Core applicable population (clinical patients)
Applicable populationApplication purposeJudgment basis
Hypertriglyceridemia (HTG) patientsAssists in the diagnosis of familial hypertriglyceridemia (FHTG), and evaluates the degree of TG metabolic disorderApoC3 inhibits the activity of lipoprotein lipase (LPL), which is a key pathogenic factor of HTG
high-risk/affected patient group of atherosclerotic cardiovascular disease (ASCVD) Assess CVD risk and predict major adverse cardiovascular events (MACE)Elevated ApoC3 and small and dense LDL-C particles HDL-C function impairment is directly related to CVD risk predictors that are independent of traditional lipid indicators
Metabolic syndrome (MetS) patientsauxiliary diagnosis of MetS, assessment of metabolic disorder, monitoring of intervention effectApoC3 level is positively related to MetS core characteristics such as insulin resistance, obesity, hypertension
type 2 diabetes patientsassessment of dyslipidemia risk, monitoring of microvascular complications (For example, diabetes nephropathy) progressApoC3 level is related to blood glucose control status and risk of diabetes complications
high-risk population of acute pancreatitisscreening HTG related pancreatitis risk (TG> 1000mg/dL)Elevated ApoC3 is one of the important mechanisms of HTG induced acute pancreatitis
Patients with non-alcoholic fatty liver disease (NAFLD)Assist in the diagnosis of NAFLD, evaluate the degree of liver damage, monitor and treat metabolic improvementThe liver is the main site of ApoC3 synthesis, and ApoC3 levels are abnormal during liver disease
Patients with mixed dyslipidemiaOptimize the CVD risk assessment model (combining LDL-C, HDL-C, non-HDL-C) - C class)Residual risks that cannot be covered by traditional blood lipid indicators alone, ApoC3 can be supplemented
II. Special populations that need to be monitored
PopulationMonitoring purpose
Patients treated with statins/beta drugsMonitoring changes in ApoC3, predicting lipid-lowering efficacy, and guiding personalized medication dosage adjustment
Users of new lipid-lowering drugs such as PCSK9 inhibitors/antisense oligonucleotides (such as Volanesorsen)Evaluating the regulatory effect of drugs on ApoC3 levels as a therapeutic indicator for targeted therapy
Patients with familial dyslipidemia and their first-degree relativesGenetic risk assessment, early screening
Obese/overweight populationEvaluate insulin resistance and long-term CVD risk
3、 Health check-up population (non patients)
As a supplementary indicator for blood lipid profile testing, it is suitable for:
Healthy individuals who wish to comprehensively evaluate their lipid metabolism status during routine check ups
People with a family history of CVD but temporarily "normal" blood lipid indicators (traditional indicators are normal but there is still residual risk for those with elevated ApoC3)
Sub healthy individuals who require personalized health advice and early intervention
Fourth, research applicable population (limited to ELISA/CLAI kits)
Some ApoC3 ELISA kits are labeled as "for scientific research use only, not for clinical diagnosis"
This type of kit is suitable for:Researchers who need to detect ApoC3 levels in serum, plasma, tissue homogenates, and cell culture supernatants of various genera such as humans/rats/mice/rabbits in basic research
The research group involved in diabetes, obesity, cardiovascular disease, lipid metabolism and other fields
summed up a sentence
The applicable population of the apolipoprotein C3 test kit can be summarized as: "the people with abnormal blood lipids, high cardiovascular risk, diabetes and fatty liver, taking lipid-lowering drugs, and taking more comprehensive physical examination can also be checked." Its greatest value lies in filling the blind spot of the four traditional blood lipids (TC, TG, LDL-C, HDL-C), especially for those with traditional indicators that "look good" but actually have high residual risk.
source:http://en.zjikon.com/news1084746.html